VolitionRX Ltd (NYSEAMERICAN:VNRX) CEO Cameron John Reynolds purchased 4,000 shares of VolitionRX stock in a transaction that occurred on Friday, May 22nd. The shares were bought at an average price of $3.00 per share, with a total value of $12,000.00.
NYSEAMERICAN:VNRX traded down $0.02 on Friday, hitting $3.03. The stock had a trading volume of 541,700 shares, compared to its average volume of 173,223. VolitionRX Ltd has a 1-year low of $2.22 and a 1-year high of $6.84.
VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Thursday, May 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The business had revenue of $0.54 million during the quarter.
Several large investors have recently modified their holdings of the stock. California Public Employees Retirement System purchased a new stake in shares of VolitionRX in the 4th quarter valued at approximately $97,000. State Street Corp acquired a new stake in VolitionRX in the 4th quarter valued at approximately $58,000. Advisor Group Inc. increased its holdings in VolitionRX by 33.9% in the 4th quarter. Advisor Group Inc. now owns 19,770 shares of the medical research company’s stock valued at $94,000 after purchasing an additional 5,000 shares during the last quarter. Oxford Asset Management LLP acquired a new position in VolitionRX during the fourth quarter worth $58,000. Finally, Morgan Stanley boosted its position in shares of VolitionRX by 9.9% during the first quarter. Morgan Stanley now owns 220,625 shares of the medical research company’s stock worth $686,000 after buying an additional 19,900 shares during the period.
VNRX has been the topic of several recent research reports. Aegis initiated coverage on VolitionRX in a report on Wednesday, May 6th. They set a “buy” rating and a $10.00 target price on the stock. Maxim Group started coverage on VolitionRX in a research note on Friday, May 8th. They set a “buy” rating and a $8.00 price objective on the stock. Finally, Oppenheimer started coverage on VolitionRX in a report on Sunday, May 10th. They issued a “buy” rating and a $7.00 target price for the company.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Further Reading: Earnings Per Share (EPS)
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.